Published in Clin Genet on February 11, 2010
GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. Biochim Biophys Acta (2011) 0.97
Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB₁ alleles causing GM1-gangliosidosis and Morquio B disease. J Inherit Metab Dis (2011) 0.78
Three novel beta-galactosidase gene mutations in Han Chinese patients with GM1 gangliosidosis are correlated with disease severity. J Biomed Sci (2010) 0.75
Clinical Findings and Natural History in Ten Unrelated Families with Juvenile and Adult GM1 Gangliosidosis. JIMD Rep (2015) 0.75
β-Galactosidosis in Patient with Intermediate GM1 and MBD Phenotype. JIMD Rep (2012) 0.75
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest (2004) 4.54
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet (2009) 4.02
Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis (2005) 2.40
Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome. Biochem Biophys Res Commun (2000) 2.40
Sanfilippo syndrome: a mini-review. J Inherit Metab Dis (2008) 2.35
Chronic arsenic toxicity in Bangladesh and West Bengal, India--a review and commentary. J Toxicol Clin Toxicol (2001) 2.25
Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol (2001) 2.17
A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 2.12
Mechanical strength of repairs of the rotator cuff. J Bone Joint Surg Br (1994) 2.12
Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med (2000) 2.07
Hip damage occurs at the zone of femoroacetabular impingement. Clin Orthop Relat Res (2008) 2.06
Pipecolic acid elevation in plasma and cerebrospinal fluid of two patients with pyridoxine-dependent epilepsy. Ann Neurol (2000) 2.01
Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet (1999) 1.99
Protonation states of membrane-embedded carboxylic acid groups in rhodopsin and metarhodopsin II: a Fourier-transform infrared spectroscopy study of site-directed mutants. Proc Natl Acad Sci U S A (1993) 1.97
GJA12 mutations are a rare cause of Pelizaeus-Merzbacher-like disease. Neurology (2007) 1.93
Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. Clin Chem (1989) 1.91
Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis (2009) 1.89
The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet (2004) 1.79
An evaluation of an electric pulp tester as a measure of analgesia in human vital teeth. J Endod (1987) 1.79
Insect immunity. I. Characteristics of an inducible cell-free antibacterial reaction in hemolymph of Samia cynthia pupae. Infect Immun (1974) 1.78
Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2000) 1.77
Multidisciplinary management of Hunter syndrome. Pediatrics (2009) 1.76
Effect of systemic penicillin on pain in untreated irreversible pulpitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2000) 1.74
Biosynthesis of proteodermatan sulfate in cultured human fibroblasts. J Biol Chem (1984) 1.71
Microinjection and growth of bacteria in the cytosol of mammalian host cells. Proc Natl Acad Sci U S A (2001) 1.71
Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet (2005) 1.67
Genetic and phenotypic heterogeneity in disorders of peroxisome biogenesis--a complementation study involving cell lines from 19 patients. Pediatr Res (1989) 1.67
Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta (2010) 1.65
Treatment of bilateral superior oblique tendon sheath syndrome complicating rheumatoid arthritis. Br J Ophthalmol (1980) 1.62
Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet (2009) 1.61
White matter lesion severity in male and female patients with Fabry disease. Neurology (2005) 1.61
Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation. Science (1988) 1.60
Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis (2009) 1.58
Total hip arthroplasty in young adults after failed triple innominate osteotomy. J Arthroplasty (2001) 1.57
A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IV A). Clin Chim Acta (1990) 1.57
Investigating the microenvironments of inhomogeneous soft materials with multiple particle tracking. Phys Rev E Stat Nonlin Soft Matter Phys (2001) 1.56
Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis (2001) 1.56
An improved two dimensional thin-layer chromatography system for the separation of phosphatidylglycerol and its derivatives. J Lipid Res (1976) 1.54
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis (2003) 1.52
Clinical and neuropsychological outcome in 33 patients with biotinidase deficiency ascertained by nationwide newborn screening and family studies in Austria. Eur J Pediatr (2001) 1.50
Phospholipase A2 is present in meconium and inhibits the activity of pulmonary surfactant: an in vitro study. Acta Paediatr (2001) 1.50
Distinct phosphatidylinositol 3-kinase lipid products accumulate upon oxidative and osmotic stress and lead to different cellular responses. J Biol Chem (1999) 1.49
Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve (2002) 1.47
Cardiovascular effects of intraosseous injections of 2 percent lidocaine with 1:100,000 epinephrine and 3 percent mepivacaine. J Am Dent Assoc (1999) 1.47
Mutant NDUFV1 subunit of mitochondrial complex I causes leukodystrophy and myoclonic epilepsy. Nat Genet (1999) 1.46
Genetic assessment of familial and early-onset Parkinson's disease in a Greek population. Eur J Neurol (2013) 1.43
Bone marrow transplantation for autosomal recessive osteopetrosis. A report from the Working Party on Inborn Errors of the European Bone Marrow Transplantation Group. J Pediatr (1994) 1.42
Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome. Clin Genet (2007) 1.41
Primary amoebic lung abscess. J Assoc Physicians India (1992) 1.39
Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function. J Pediatr (1999) 1.37
Horse chestnut seed extract. Lancet (1990) 1.37
An evaluation of volumes and concentrations of lidocaine in human inferior alveolar nerve block. J Endod (1989) 1.36
BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model. J Allergy Clin Immunol (1998) 1.35
Sanfilippo disease type D: deficiency of N-acetylglucosamine-6-sulfate sulfatase required for heparan sulfate degradation. Proc Natl Acad Sci U S A (1980) 1.33
Autosomal recessive osteopetrosis: diagnosis, management, and outcome. Arch Dis Child (2000) 1.32
Anesthetic efficacy of the intraosseous injection after an inferior alveolar nerve block. J Endod (1996) 1.32
Anesthetic efficacy and heart rate effects of the supplemental intraosseous injection of 2% mepivacaine with 1:20,000 levonordefrin. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1999) 1.30
Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis (2009) 1.30
Molecular basis of mucopolysaccharidosis type II: mutations in the iduronate-2-sulphatase gene. Hum Mutat (1993) 1.29
[Femoroacetabular impingement: trigger for the development of coxarthrosis]. Orthopade (2006) 1.29
Anesthetic efficacy of the supplemental intraosseous injection of 3% mepivacaine in irreversible pulpitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1997) 1.29
Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet (2001) 1.29
Ultrastrong coupling of the cyclotron transition of a 2D electron gas to a THz metamaterial. Science (2012) 1.27
Anesthetic efficacy of the supplemental intraosseous injection of 2% lidocaine with 1:100,000 epinephrine in irreversible pulpitis. J Endod (1998) 1.26
Fabry disease: a review of current management strategies. QJM (2010) 1.24
The total free radical trapping ability of cord blood plasma in preterm and term babies. Pediatr Res (1989) 1.23
Disordered breathing during sleep in patients with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol (2001) 1.21
Pharmacologic differentiation between endothelium-dependent relaxations sensitive and resistant to nitro-L-arginine in coronary arteries. J Cardiovasc Pharmacol (1994) 1.21
An evaluation of the incisive nerve block and combination inferior alveolar and incisive nerve blocks in mandibular anesthesia. J Endod (1992) 1.21
Free nerve endings in the ligamentum capitis femoris. Acta Orthop Scand (2000) 1.20
Molecular approaches to enteroviral diagnosis in idiopathic cardiomyopathy and myocarditis. J Am Coll Cardiol (1990) 1.19
Stress-related immune suppression: health implications. Brain Behav Immun (1987) 1.18
Mucopolysaccharidosis type I: identification of 8 novel mutations and determination of the frequency of the two common alpha-L-iduronidase mutations (W402X and Q70X) among European patients. Hum Mol Genet (1994) 1.18
Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. Mol Genet Metab (2007) 1.18
Anesthetic efficacy of the mylohyoid nerve block and combination inferior alveolar nerve block/mylohyoid nerve block. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1999) 1.17
Developmental motoneuron cell death and neurotrophic factors. Cell Tissue Res (2000) 1.17
Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes. Eur J Hum Genet (1999) 1.17
Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol Genet Metab (2013) 1.17
An evaluation of 4% prilocaine with 1:200,000 epinephrine and 2% mepivacaine with 1:20,000 levonordefrin compared with 2% lidocaine with:100,000 epinephrine for inferior alveolar nerve block. Anesth Prog (1992) 1.16
Diagnosis and management of trimethylaminuria (FMO3 deficiency) in children. J Inherit Metab Dis (2006) 1.16
Dipole coupling of a double quantum dot to a microwave resonator. Phys Rev Lett (2012) 1.15
Os acetabuli in femoro-acetabular impingement: stress fracture or unfused secondary ossification centre of the acetabular rim? Hip Int (2009) 1.15
Two novel mutations in the GDAP1 and PRX genes in early onset Charcot-Marie-Tooth syndrome. Neuropediatrics (2008) 1.15
Anesthetic efficacy of the intraosseous injection in maxillary and mandibular teeth. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1996) 1.15
Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr (1995) 1.14
Lipoprotein Lp(a). A risk factor for myocardial infarction. Arteriosclerosis (1988) 1.14
Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr (2007) 1.14
Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax (2002) 1.13
Anesthetic efficacy of a combination of hyaluronidase and lidocaine with epinephrine in inferior alveolar nerve blocks. Anesth Prog (2001) 1.13
Anesthetic efficacy of the intraosseous injection of 2% lidocaine (1:100,000 epinephrine) and 3% mepivacaine in mandibular first molars. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1997) 1.13
An evaluation of 4% prilocaine and 3% mepivacaine compared with 2% lidocaine (1:100,000 epinephrine) for inferior alveolar nerve block. J Endod (1993) 1.13
Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. Hum Mol Genet (2000) 1.13
Depletion of mitochondrial DNA in the liver of a patient with lactic acidemia and hypoketotic hypoglycemia. J Pediatr (1996) 1.13
Entry point soft tissue damage in antegrade femoral nailing: a cadaver study. J Orthop Trauma (2001) 1.12
The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess (2012) 1.12
Oligogalacturonide defense signals in plants: large fragments interact with the plasma membrane in vitro. Proc Natl Acad Sci U S A (1995) 1.11
Carpal tunnel syndrome in the mucopolysaccharidoses and mucolipidoses. J Bone Joint Surg Br (1997) 1.11
The use of ultrasound for guiding needle placement for inferior alveolar nerve blocks. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1999) 1.11
Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype. J Inherit Metab Dis (1993) 1.11